ReviewFrontiers in cardiovascular medicine2026
Atrial fibrillation and acute myocardial infarction: a Two-Way relationship.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards individualised multi-morbidity predictions: a new frontier for AI-enabled diagnostics in thrombotic disease.Indian journal of thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) and coronary artery disease (CAD) are among the most frequent cardiovascular diseases and leading causes of morbidity/mortality worldwide. The concomitant presence of AF and CAD is relatively common, as the association is supported not only by shared atherosclerotic risk factors, but also by a pathophysiological link. Patients with a history of AF have been described as at increased risk of CAD, in particular acute myocardial infarction (AMI), through several mechanisms, such as increased oxidative stress, systemic inflammation, increased platelet aggregation. On the other hand, up to 10% of patients with AMI are at risk of developing new-onset atrial fibrillation (NOAF). In the past, any type of NOAF during AMI was considered identical and equally associated with a worse outcome. More recently, increasing evidence supports the pathophysiological and nosological difference between early NOAF (occurring within the first 24 h after the index event and associated with atrial ischaemia, oxidative stress and a better outcome) and late NOAF (occurring after 24 h and correlated with increased left atrial pressures, deterioration of haemodynamic status, elevated left ventricular filling pressures and a worse outcome). In this review, we summarise the available evidence on the epidemiology, pathophysiology, risk stratification, and management of the complex two-way relationship between AF and CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.